Orally Bioavailable Enzymatic Inhibitor of CD38, <b>MK-0159</b>, Protects against Ischemia/Reperfusion Injury in the Murine Heart
作者:Bharat Lagu、Xinyuan Wu、Santosh Kulkarni、Rakesh Paul、J. David Becherer、Lyndsay Olson、Stella Ravani、Athanasia Chatzianastasiou、Andreas Papapetropoulos、Sylvia Andrzejewski
DOI:10.1021/acs.jmedchem.2c00688
日期:2022.7.14
major nicotinamide adenine dinucleotide (NAD+)- and nicotinamide adenine dinucleotide phosphate (NADP+)-consuming enzymes in mammals. NAD+, NADP+, and their reduced counterparts are essential coenzymes for numerous enzymatic reactions, including the maintenance of cellular and mitochondrial redox balance. CD38 expression is upregulated in age-associated inflammation as well as numerous metabolic diseases
CD38 是哺乳动物中主要的烟酰胺腺嘌呤二核苷酸 (NAD + ) 和烟酰胺腺嘌呤二核苷酸磷酸 (NADP + ) 消耗酶之一。NAD +、NADP +和它们的还原对应物是许多酶促反应的必需辅酶,包括维持细胞和线粒体氧化还原平衡。CD38 表达在与年龄相关的炎症以及许多代谢疾病中上调,导致细胞和线粒体功能障碍。最近的文献研究表明,CD38 在缺血/再灌注 (I/R) 时被激活,导致 NADP +耗竭,导致心脏内皮损伤和心肌梗塞。尽管越来越多的证据表明 CD38 参与各种疾病状态,但迄今为止报道的 CD38 酶抑制剂相对较少。在此,我们描述了一种在体外试验中抑制 CD38的 CD38 酶抑制剂(MK-0159,IC 50 = 3 nM 针对鼠 CD38)。与用 NAD +前体(烟酰胺核苷)或已知的 CD38 抑制剂78c治疗的小鼠相比,用MK-0159治疗的小鼠在心脏 I/R 损伤时显示出对心肌损伤的强大保护作用。